Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of ARM210 in RYR1-RM
NCT04141670Phase 1Completed
- Sponsor
- RyCarma Therapeutics
- Start
- Aug 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Surlorian in RYR1-related myopathy (RYR1-RM) (2 arms), sponsored by RyCarma Therapeutics. Primary endpoint: Number of Participants Experiencing Adverse Events When Treated With S48168 (ARM210) at 42 days. Started Aug 2020; status: completed.
02
Drugs
Surlorian
03
Conditions
RYR1-related myopathy (RYR1-RM)
Beyond the preview
Go deeper on NCT04141670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04141670.